

H2A  
HB  
12/6/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: FANG *et al.*

Application No.: To be assigned  
(Division of Appl. No. 09/640,725)

Group Art Unit: 1614

Examiner: W. Jarvis

Filed: Concurrently herewith

Attorney Docket No.: 4821-439

For: BUPROPION METABOLITES AND  
METHODS OF THEIR SYNTHESIS  
AND USE

**PRELIMINARY AMENDMENT**

**Box Patent Application**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Applicants request that the following amendments and remarks be considered by the Examiner and entered into the file of the application.

**IN THE CLAIMS**

Please cancel claims 8-18 without prejudice.

**IN THE SPECIFICATION**

Please delete lines 4-7 of the specification and add the following paragraph:

M --This is a division of application no. 09/640,725, filed August 18, 2000, which is a continuation-in-part of application no. 09/510,241, filed February 22, 2000, which claims the benefit of provisional application nos. 60/122,277, filed March 1, 1999 and 60/148,324, filed August 11, 1999, each of which is incorporated herein by reference.--

**REMARKS**

Claims 1-7 and 20-126 appear in this application for the Examiner's review and consideration. Claims 8-18 have been canceled without prejudice.

The specification has been amended to recite the priority information of the present application.